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Abstract 
Introduction:   
Precocious puberty (PP) is one of the most common reasons for referral to pediatric 
endocrinologists worldwide. Gonadotropin-releasing hormone analogs (GnRHas) are the gold 
standard for the treatment of central precocious puberty (CPP) and have an impressive track 
record of safety and efficacy. However, ongoing refinements in diagnosis and management 
continue to lead to important advancements in clinical care.  
Areas Covered: The aim of this review is to cover current considerations and controversies 
regarding the diagnosis of CPP, as well as new findings in regards to etiology and treatment 
modalities. 
Expert Commentary: There is emerging evidence of monogenic etiologies of CPP and significant 
progress in the expansion of newer formulations of GnRHas. Despite these exciting developments, 
areas of uncertainty in the diagnosis and treatment of CPP remain. While long-term outcomes of 
patients treated for CPP are encouraging, only short-term follow-up is available with respect to the 
newer extended-release GnRHa preparations, and how they compare with historically used 
formulations is unknown. A particular shortage of information exists pertaining to CPP in boys 
and regarding the psychological implications of early puberty in girls, and more research is needed. 
Continued investigation will yield new insights into the underlying genetics and optimal treatment 
strategies for CPP.  
1. Introduction
____________________________________________________
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Precocious puberty (PP) has been historically defined as the development of secondary sexual 
characteristics before the age of 9 years in boys, 7 ½ years in African American and Hispanic 
girls and 8 years in Caucasian girls [1]. During the last several decades, this classic definition has 
been challenged by accumulating data suggesting a trend of an earlier onset of puberty, 
particularly in girls, and revised guidelines recommending a lower age threshold for PP have 
been advocated. However, due to concerns about missing pathology as well as the observation 
that the average age of menarche has not changed, the general consensus is that the traditional 
age cut-offs for PP remain appropriate in the clinical setting [2]. 
The three major categories of PP are central PP, peripheral PP and benign variants. Central 
precocious puberty (CPP) is caused by early maturation of the hypothalamic-pituitary-gonadal 
(HPG) axis, and will be the sole focus of this review. Although the onset is earlier, the pattern 
and timing of pubertal events are the same as in normally timed puberty. The initial clinical sign 
of CPP in girls is breast development. The growth spurt usually occurs during breast Tanner 
stage 2-3, followed by the first menstrual period which typically occurs at Tanner stage 4. The 
initial clinical sign of CPP in boys is testicular enlargement. The growth spurt happens later as 
compared to girls [3, 4]. Both boys and girls with CPP have accelerated linear growth for age, an 
advanced bone age, and pubertal levels of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH).  
The initiation of puberty is a complex process with multiple levels of regulation. Although the 
exact mechanism is still unknown, the first biochemical event that initiates HPG axis activation 
is a rise in kisspeptin [3]. This is followed by activation of the GnRH pulse generator resulting in 
an increase in LH pulse amplitude initially at night and subsequently also during the day. This in 
turn is followed by a rise in estrogen and testosterone production from the gonads. 
CPP can be idiopathic, due to genetic mutations or associated with central nervous system (CNS) 
abnormalities or insults. Regardless of the cause, safe and effective treatment exists in the form 
of gonadotropin-releasing hormone analogs (GnRHas) with the major goal of intervention being 
the prevention of short final adult height. In this review, we will provide an update of the 
etiologies of CPP along with diagnostic and treatment considerations, therapeutic options and 
long-term outcomes.  
2. Etiology:  
CPP is far more common in girls than in boys [5, 6]. It is idiopathic in 80 to 90 percent of cases 
in girls, whereas intracranial lesions are detected in more than half of cases involving boys [1, 7]. 
Risk factors for CPP include congenital or acquired CNS disorders as well as international 
adoption. Several genetic syndromes are also associated with CPP [3]. Secondary CPP can occur 
in patients who initially present with peripheral PP, particularly when the bone age is 
significantly advanced. Familial cases have been reported as well [8, 9]. Table 1 summaries 
etiologies and known risk factors for CPP. 
There has been exciting emerging evidence from several ongoing investigations of genetic 
causes of CPP during the past decade. These include rare genetic mutations in the gene encoding 
for kisspeptin (KISS1) and its receptor (KISS1R) which were found in patients with CPP resulting 
in an increased amplitude of GnRH pulsatility and/or prolonged intracellular signaling [10-12]. 
However, the most common mutation found in both sporadic and familial CPP thus far is in the 
imprinted gene MKRN3 which encodes for makorin ring finger 3 [13-15]. Animal studies have 
demonstrated that a decline in mkrn3 expression is correlated with a rise in kiss1 expression, 
leading to the supposition that down-regulation of MKRN3 is permissive for GnRH pulses during 
puberty [15]. Therefore, deficiency of MKRN3 would be expected to result in a loss of inhibition 
of HPG axis activation. A second imprinted gene, DLK1, has also been implicated in kindreds 
with CPP in which expression is limited to individuals inheriting the paternal allele [16]. Single 
nucleotide polymorphisms (SNPs) in the FSHB gene and the LHB gene [17] and mutations in the 
Y1 subtype receptor for neuropeptide Y could also theoretically cause PP but have not been 
proven to yet. Interestingly, several genes involved in hypothalamic hamartomas have been 
found to have increased expression in patients with CPP [18], and great strides in elucidation of 
the genetic underpinnings of the condition will undoubtedly continue. Table 2 describes the 
genetic mutations that have been discovered to form the basis of CPP along with their putative 
physiologic effect on the regulation of the HPG axis. 
3. Diagnosis 
3.1. Clinical Signs 
Girls with CPP usually present with breast development with or without pubic hair. When 
present, clinical evidence of both estrogen and androgens is important in differentiating CPP 
from benign premature thelarche. Boys will present with bilateral testicular enlargement as 
opposed to boys with peripheral PP in whom the testes are prepubertal or only slightly enlarged. 
CPP is also characterized by ongoing pubertal progression as well as growth acceleration and 
advanced skeletal maturation. 
3.2. Laboratory evaluation: 
A GnRH stimulation test is the gold standard for the diagnosis of CPP. However, synthetic 
GnRH is no longer available in the United States. Therefore, GnRHas have been used instead. A 
multitude of different protocols have been suggested, ranging from single sample LH levels to 
abbreviated or prolonged algorithms involving serial LH testing (19, 20). Regardless of which of 
these tests is used, a peak stimulated LH level of ~ 4-6 mIU/L [21] or an LH/ FSH ratio >0.66 is 
considered pubertal by many endocrinologists [22, 23]. With the increasing sensitivity of LH 
assays, a random ultrasensitive LH level is now used in lieu of stimulation testing by many 
centers. An LH level > 0.2–0.3 (depending on the assay) is considered consistent with CPP [24, 
25]. However, one should keep in mind that basal ultrasensitive LH is often prepubertal in early 
CPP and may be falsely reassuring [1]. Measurement of sex steroids (basal or stimulated) is not 
diagnostic alone but can be helpful as supportive data in ambiguous cases, particularly serum 
testosterone levels. In contrast, random estradiol levels are often unmeasurable even in girls in 
whom puberty is significantly advanced.  
3.3. Imaging:  
Pelvic ultrasonography has been used in the evaluation of precocious puberty. It is specifically 
useful in equivocal cases since uterine and ovarian dimensions have a stronger correlation with 
bone age than with chronological age and are correlated with CPP up to the age of 8 years [26].  
As would be expected, girls with CPP have larger uterine and ovarian volumes as compared to 
girls who are prepubertal and girls with premature thelarche. However, diagnostic thresholds for 
uterine and ovarian volumes are variable and there is significant overlap between patients with 
CPP and other benign variants. [26, 27, 28]. Also, the finding of small ovarian follicles on a 
pelvic ultrasound is normal even in prepubertal girls [29]. Needless to say, ultrasound is 
technician dependent and difficult to standardize, and its routine use in the evaluation of early 
puberty in girls varies significantly between different centers. 
Once CPP is confirmed with laboratory testing, a brain MRI is considered to rule out the 
presence of CNS abnormalities. Given the high prevalence of CNS abnormalities in males, it is 
recommended that all boys with CPP undergo brain imaging [7, 30]. However, the prevalence of 
CNS abnormalities in girls is much lower, varying between 0% and 27% among different studies 
and decreases with increasing age [31-33]. Because some of these rates include incidental 
lesions, the actual prevalence of brain tumors and other pathology requiring intervention is even 
smaller [34]. A meta-analysis based on 15 studies comprising a total of 1853 patients found an 
overall rate of abnormal MRIs of 9% which decreased to 7% when only girls with CPP older 
than 6 years were included (35). Based on these data and in light of discussions regarding the 
decreasing age of normal puberty, it is hard to justify routine brain MRI scanning in all girls 
presenting with puberty before the age of 8. It has been suggested that girls with CPP should 
have a brain MRI performed routinely only if they are younger than 6 years of age [2] or have 
neurological symptoms. However, cranial MRI continues to be performed routinely in many 
centers in all the girls presenting with breast development before the age of 8 due to the risk of 
finding an occult intracranial lesion.  
4. Treatment 
4.1 Goals of Treatment 
The main goal of CPP treatment is to preserve final adult height. However, some patients have a 
nonprogressive or slowly progressive form of CPP and achieve their genetic potential for height 
without intervention. Depending on the child’s age and the degree of sexual maturation, 6-12 
months of observation might be necessary to monitor pubertal progression. If there is minimal 
change in Tanner staging and if growth velocity remains less than 5-6 cm/yr, it is considered to 
be slowly progressing. However, even in patients with clear progression of CPP, the degree of 
height gain is quite variable after treatment. Therefore, the main dilemma for the endocrinologist 
is to decide if a patient with CPP needs treatment or not. Multiple parameters need to be 
considered in order to make this decision including chronological age, the rate of sexual 
maturation, growth velocity and estimated final height together with the degree of bone age 
advancement. 
Age: Many studies have indicated that girls less than 6 years old who have rapid pubertal 
progression attain the most benefit from the treatment in terms of increasing adult height [2]. 
While girls between the age of 6-8 years have a variable outcome, girls older than 8 years and 
those with slowly progressive CPP do not derive any benefit and may even lose height potential 
as a result of treatment [3, 36]. Ironically, the vast majority of girls referred for PP are older than 
age 6 and studies have indicated that many girls being treated with GnRHas for CPP were older 
than 8 years when therapy was started [37]. There are scarce data for boys because there are far 
fewer boys than girls with CPP. Regardless, existing data suggest a significant improvement in 
final height after treatment of CPP in boys [38]. An expert panel concluded that it is reasonable 
to consider GnRHa treatment in boys with progressive CPP if they present before nine years of 
age. As in girls, GnRHa therapy results in less height gain for boys with a more advanced bone 
age at the initiation of therapy. 
Tempo of sexual maturation: The tempo of sexual maturation is also an important factor in 
determining the necessity of treatment. If it is slow, early puberty is less likely to compromise 
final adult height and treatment is not necessary [39]. In a study of 16 such girls who were 
followed for 12 years without treatment, all reached a normal adult height [40]. Despite the early 
onset of breast development in this group, menarche occurred at a normal age. Also, in a study 
group of 35 boys with slowly progressive puberty who were not treated, adult height was found 
within the range of their target height [41].  
Predicted adult height: There are many different methods that can be used to predict final adult 
height. One should keep in mind that height prediction methods usually over-predict the adult 
height in children with PP. The most commonly used method was developed by Bayley and 
Pinneau and provides a table to predict final adult height based upon the child's bone age and 
absolute height. If the estimated adult height is above 150 cm in girls and above 160 cm in boys, 
treatment is probably not needed to achieve normal adult height. [42].  
The other frequently stated goal of treatment in CPP is to relieve potential psychosocial stress 
caused by early pubertal changes. Parents are usually concerned about early menses, which can 
be stressful for a young girl as well as her mother. Literature to date has linked precocious 
puberty to higher rates of depression, suicidal thoughts and behavioral problems than in girls 
with later-than-average development [43-47]. This prompted some to consider psychological 
distress as an indication to treat CPP in children. However, in contrast, other studies have failed 
to find any differences in self-image, self-esteem, or behavioral issues in children with 
precocious puberty when compared to population norms [48, 49]. Evidence regarding 
psychological benefit from treatment was deemed inconclusive by the GnRHa Consensus 
Conference, and more investigation in this area is badly needed [2]. 
Needless to say, when CPP is caused by a CNS lesion, the underlying pathology should also be 
treated.  
4.2. Treatment Options 
GnRHas are standard of care for the treatment of CPP. These agents stimulate the pituitary 
gonadotrophs in a continuous fashion as opposed to the physiologic pulsatile secretion of 
hypothalamic GnRH. This continuous stimulation leads to suppression of gonadotropins, 
resulting in decreased sex steroid production.  
GnRHas are derived from native GnRH but contain modifications that result in increased 
potency and a longer half-life. They were initially approved for the treatment of prostate cancer. 
After a study showing that treatment with a GnRHa slowed growth velocity and bone age 
advancement and increased predicted final height in children with CPP [50], the monthly version 
Lupron Depot was approved by the FDA in 1993. This long-acting GnRHa in the form of 
monthly intramuscular leuprolide acetate was prescribed almost exclusively for the treatment of 
CPP in the U.S. for many years. Three-monthly depot preparations, also administered via 
intramuscular injection, have also been used to treat CPP, particularly in Europe [51]. Several 
studies as well as a meta-analysis have suggested that the degree of biochemical suppression 
achieved with 3-monthly dosing is consistently less than that seen with monthly GnRHa 
administration [51-54]. However, the clinical response to treatment appears 
to be similar based on limited data. Several other GnRHas have been developed through the 
years and used for the treatment of CPP including a subcutaneous implant containing histrelin 
and a six-monthly formulation of triptorelin (Triptodur) that was approved by the FDA for the 
treatment of CPP in 2017. Similar to other long-acting intramuscular GnRHa preparations, 
Triptodur has been shown to be effective and safe in children with CPP [55]. Additional 6-
monthly forms of GnRHas are being investigated with promising initial results.  
The initial histrelin implant (Vantus) was first developed for the treatment of metastatic prostate 
cancer. A similar device (Supprelin) was approved by the FDA in 2007 after it was shown that it 
suppressed LH and sex steroid concentrations for at least 1 year. The subcutaneous implant 
allows for sustained release of the potent GnRHa histrelin, and requires a minor outpatient 
surgical procedure for implantation and removal, which are usually performed under local 
anesthesia [56]. The device is usually placed in the inner aspect of the upper arm. An initial pilot 
study in 11 girls previously treated with depot triptorelin revealed satisfactory maintenance of 
LH and FSH suppression following placement of a histrelin implant. Clinical evidence was also 
promising and included regression of breast development, decreased growth velocity, and 
attenuation in the rate of skeletal maturation during 15 months of treatment. Less discomfort and 
lifestyle interference as compared to monthly injections was another plus from this study [57]. 
This was followed by a phase III study in 36 patients with CPP (20 naïve) that demonstrated 
profound suppression of the HPG axis within 1 month of placement of the histrelin implant [58]. 
The extension phase of this study revealed a significant improvement in predicted adult height 
after up to 6 years of sequential annual histrelin implants [59]. However, an important 
advancement has been the establishment that a single histrelin implant lasts at least 2 years. This 
was demonstrated in a study involving 33 children with CPP in whom a single implant was left 
in place for 2 years [60]. Peak stimulated LH levels at 12 and 24 months were equivalent, and 
clinical parameters of CPP improved progressively. Use of a single implant for 2 years decreases 
the cost and numbers of surgical procedures in children treated with this modality. 
Other formulations include a daily subcutaneous injection and an intranasal spray with a multiple 
daily dosing schedule. The biggest concern with these formulations is compliance and 
subsequent failure of HPG axis suppression. Thus, they are rarely used in the clinical arena. 
Table 3 illustrates the most commonly used GnRHas along with their respective routes of 
administration, doses and durations of action.  
Several adjunctive treatments above and beyond GnRHas have been proposed for the treatment 
of CPP including aromatase inhibitors and growth hormone. However, there is no clear evidence 
at present to support these in routine CPP treatment. 
4.3. Monitoring 
After GnRHa therapy has begun, close monitoring should be performed to ensure that the goals 
of treatment are being achieved including adequate suppression of the HPG axis, slowing of 
development of secondary sexual characteristics and diminution in the pace of bone age 
advancement. Routine monitoring should include evaluation of pubertal development and linear 
growth velocity along with periodic bone age xrays which are customarily performed annually. 
Whether routine monitorization of serum LH and sex steroid concentrations during GnRHa 
therapy is necessary is controversial. There are insufficient data to demonstrate that using these 
measurements to adjust therapy improves adult height outcomes. However, if there is evidence 
of ongoing pubertal progression once therapy has begun, these measurements may be used to 
assess whether complete suppression of the HPG axis has been achieved. If this testing suggests 
incomplete suppression, the GnRHa dose should be increased or the interval between doses 
should be decreased. It is essential to note, however, that random ultrasensitive LH 
concentrations often fail to revert to prepubertal values even when the HPG axis is fully 
suppressed [61]. Thus, a GnRHa stimulation test should be used to confirm lack of suppression 
when the clinical index of suspicion is high. Baring non-compliance, however, true treatment 
failure in a child with CPP who is receiving standard doses of a GnRHa is almost unheard of and 
should prompt an investigation for alternate sources of sex steroid exposure.  
Patients and families should be warned that signs of adrenarche such as pubic and axillary hair 
development will continue to progress and do not reflect treatment inadequacy. In a similar 
manner, vaginal bleeding might occur within the first weeks following the initial dose of a 
GnRHa due to estrogen withdrawal. However, if this happens later during the treatment course, 
inadequate treatment or other possible etiologies must be considered. 
5. Adverse events and long-term concerns 
Overall GnRHas have been shown to be remarkably safe to date. Headaches and hot flushes have 
been the two most common reported nonspecific side effects. Local skin reactions at the site of 
depot injections is another one which resolves without intervention. Rarely, sterile abscesses 
have been reported and a change in treatment modality is necessary. Additionally, the histrelin 
implant has a potential to become brittle and break upon removal and sometimes ultrasound 
guided extraction of the fragments is necessary. 
There have been several potential long-term concerns raised to date regarding GnRHa therapy. 
Some authors have claimed that BMI increases during treatment. Despite these anecdotal 
observations, no negative effect of GnRHa treatment on BMI in girls with CPP has been found in 
the vast majority of studies [62-64]. Another major concern is reduction in bone mineral density 
(BMD), which in fact has been shown to be decreased during treatment in girls due to ovarian 
suppression. However, after treatment is discontinued, BMD is regained, and so women are not 
significantly different from their peers without a history of CPP [62]. There has been some 
discussion regarding the incidence of polycystic ovary syndrome (PCOS) in patients treated with 
GnRHas. Studies have reported variable results with some finding markedly increased rates of 
PCOS and others finding little or no difference. Thus, there is no consensus at this point on 
whether CPP or treatment with GnRHas results in an increased risk of PCOS [63]. A final area of 
concern with GnRHa treatment pertains to reproductive function. Limited long-term follow-up 
information thus far has indicated normal fertility in treated women with CPP compared with 
controls. In contrast, untreated women with a history of CPP were found to have higher rates of 
assisted reproduction and signs of hyperandrogenism suggesting a protective effect of GnRHas 
in this regard [65]. 
6. Conclusion:  CPP is more common in girls and is usually idiopathic. Other rare etiologies 
include a wide variety of conditions such as CNS lesions, familial cases, and genetic causes 
which have been recently emerging. Clinical and laboratory evaluation is necessary for 
diagnosis, as well as imaging studies for selected cases. The decision to treat is complicated and 
cases should be evaluated carefully from all aspects. GnRHa therapy needs to be considered for a 
girl presenting with CPP before the age of six with breast and pubic hair development, advanced 
bone age, and accelerated height velocity. In a girl with somewhat later onset of CPP and/or 
historically slow progression of pubertal development without a significant increase in height 
velocity, observation for six to twelve months to understand the pace of the pubertal progression 
before making a treatment decision is recommended. For boys, all those presenting with CPP 
before the age of nine years should be treated unless there is evidence of slow pubertal 
progression. Primary treatment is a GnRHa using one of a variety of available formulations 
depending on the individual case and local health insurance approval criteria. Bone age, clinical, 
and if indicated, biochemical indices should be followed during treatment to ensure adequate 
pubertal suppression. The available evidence regarding both short and long-term outcomes 
reveals that GnRHas are safe and effective.  
7. Expert Commentary 
Despite great strides in the understanding and management of CPP, important questions remain. 
Which GnRHa stimulation testing protocol is optimal for diagnosis has not been defined, and 
whether girls older than age 6 require universal brain MRI scanning remains an active area of 
controversy. Data regarding the psychological implications of either treated or untreated CPP in 
girls are decidedly mixed, and further research in this arena should be considered a priority. Recent 
years have witnessed an exhilarating expansion in identification of monogenic etiologies of CPP 
in both familial and sporadic cases. To date, mutations in four different genes have been shown to 
form the basis for CPP, two of which are maternally imprinted. As the list of genetic causes of 
early puberty grows, the percentage of “idiopathic” cases can be anticipated to steadily decrease. 
The discovery of genetic mutations as the basis for early activation of the HPG axis also affords 
the promise of exciting novel insights into normal reproductive physiology, further illuminating 
what has historically been referred to as the “black box” of puberty! An additional area of 
tremendous progress has been in the development of newer extended release formulations of 
GnRHas above and beyond traditional depot monthly intramuscular injections. Following the 
advent of a subcutaneous implant that lasts for at least two years, 3-monthly and 6-monthly 
intramuscular injectable preparations have entered the clinical setting, resulting in an impressive 
array of therapeutic options for patients and providers. However, little head-to-head comparative 
information regarding these disparate long-acting GnRHas is available. Regardless of the 
preparation being used, whether and what specific strategy for biochemical monitoring during 
treatment with a GnRHa is needed is another topic of uncertainty. Long-term follow up of patients 
treated with a GnRHa for CPP has been uniformly reassuring in terms of BMI, bone mineral 
density and reproductive function in women. However, several spheres of investigation deserve 
attention. It is intriguing to speculate whether the identification of genetic causes of CPP will in 
turn lead to the development of new targeted therapies and/or innovative strategies for assessing 
the degree of HPG axis suppression during treatment. Whether concerns about psychological 
distress arising from CPP should be used as a rationale for treatment has not been established and 
demands further study. Although short-term clinical efficacy and safety of the available GnRHa 
formulations appears to be comparable, whether this will ultimately be confirmed by long-term 
follow up is unknown. Lastly, a substantial scarcity of knowledge pertaining to boys with CPP 
exists due to the much smaller number of affected individuals. This deficit is present in all facets 
of clinical care in boys and has implications for making treatment decisions and providing 
prognosis in terms of expected height gained. Likewise, long-term follow up of boys will be 
essential in order to interrogate important parameters such as bone health and fertility.  It is 
predicted that future research efforts will be aimed at addressing each of these issues with the 
ultimate goal of advancing knowledge and improving care of children with CPP.  
8. Key issues:  
• The majority of girls have idiopathic CPP whereas boys are more likely to have a 
pathological cause. 
• The diagnosis of CPP requires a combination of clinical and biochemical factors, as well 
as imaging studies in selected cases. 
• A brain MRI should be obtained in all boys with CPP; MRI in girls is more controversial, 
with earlier age more clearly necessitating brain MRI. 
• Identification of genetic causes of CPP is exciting but is at the beginning of its journey. 
• Girls <6 years old benefit most from the treatment. Less data exists for boys but treatment 
should be considered in boys <9 years old. 
• The gold-standard treatment for CPP is GnRHas which provide sustained high levels of 
GnRH, resulting in suppression of the HPG axis.  
• Multiple formulations of GnRHas are available and they are equally effective in terms of 
the clinical aspects of CPP. There are some minor differences observed in gonadotropin 
levels.  
• Long-term concerns of children treated with GnRHas for CPP include an increase in 
BMI, PCOS and decrease in BMD. However, results to date are reassuring. 
References 
1. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. Curr Probl 
Pediatr Adolesc Health Care. 2007;37(2):50–72.  
2. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the 
use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123: e752–
62. 
**Proceedings from a multidisciplinary international consensus conference on the use 
of GnRHas 
3. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol 
Metab. 2013;98(6): 98-207         
4. Tanner JM, Davies PSW. Clinical longitudinal standards for height and height velocity 
for North American children. J Pediatr. 1985;107(3):317–29.  
5. Soriano-Guillen L, Corripio R, Labarta JI, Canete R, Castro-Feijoo L, Espino R, et al. 
Central precocious puberty in children living in Spain: incidence, prevalence, and 
influence of adoption and immigration. J Clin Endocrinol Metab. 2010;95(9):4305–13.  
6. Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Gold-berg C, et al. Efficacy of 
leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes 
during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011(1):7. 
7. Choi KH, Chung SJ, Kang MJ, Yoon JY, Lee JE, Lee YA, et al. Boys with precocious or 
early puberty: incidence of pathological brain magnetic resonance imaging findings and 
factors related to newly developed brain lesions. Ann Pediatr Endocrinol 
Metab. 2013;18(4):183–90.  
8. de Vries L, Kauschansky A, Shohat M, Phillip M. Familial central precocious puberty 
suggests autosomal dominant inheritance. J Clin Endocrinol Metab. 2004;89(4):1794–
800.  
9. Rohn R, Rousonelos G. Familial sexual precocity. Am J Dis Child. 1986;140(8):741–2.  
10. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, et al. A GPR54-
activating mutation in a patient with central precocious puberty. N Engl J Med. 2008; 
358(7):709–15.  
** First report of a genetic mutation as the cause for CPP 
11. Luan X, Yu H, Wei X, Zhou Y, Wang W, Li P, et al. GPR54 polymorphisms in Chinese 
girls with central precocious puberty. Neuroendocrinology. 2007; 86(2):77–83.  
12. Silveira LG, Noel SD, Silveira-Neto AP, Abreu AP, Brito VN, Santos MG, et al. 
Mutations of the KISS1 gene in disorders of puberty. J Clin Endocrinol Metab. 2010; 
95(5):2276–80.  
**First description of a KISS1 mutation in a patient with CPP 
13. Abreu AP, Dauber A, Macedo DB, Noel SD, Brito VN, Gill JC, et al. Central precocious 
puberty caused by mutations in the imprinted gene MKRN3. N Engl J Med. 2013; 
368(26):2467–75.  
**Discovery of MKRN3 mutations as the basis for familial CPP 
14. Settas N, Dacou-Voutetakis C, Karantza M, Kanaka-Gantenbein C, Chrousos GP, 
Voutetakis A. Central precocious puberty in a girl and early puberty in her brother caused 
by a novel mutation in the MKRN3 gene. J Clin Endocrinol Metab. 2014; 99(4): E647–
51.  
15. Macedo DB, Abreu AP, Reis AC, Montenegro LR, Dauber A, Beneduzzi D, et al. Central 
precocious puberty that appears to be sporadic caused by paternally inherited mutations 
in the imprinted gene makorin ring finger 3. J Clin Endocrinol Metab. 2014; 99(6): 
E1097–103.  
16. Dauber A, Cunha-Silva M, Macedo DB, et al. Paternally inherited DLK1 deletion 
associated with familial central precocious puberty. J Clin Endocrinol Metab 
2017;102(5):1557e67. 
**Description of DLK1 deletion in CPP 
17. Zhao Y, Chen T, Zhou Y, Li K, Xiao J. An association study between the genetic 
polymorphisms within GnRHI, LHbeta and FSHbeta genes and central precocious 
puberty in Chinese girls. Neurosci Lett. 2010; 486(3):188–92.  
18. Parent AS, Matagne V, Westphal M, Heger S, Ojeda S, Jung H. Gene expression 
profiling of hypothalamic hamartomas: a search for genes associated with central 
precocious puberty. Horm Res. 2008; 69(2):114–23.  
19. Yazdani P, Lin Y, Raman V, et al. A single sample GnRHa stimulation test in the 
diagnosis of precocious puberty. Int J Pediatr Endocrinol 2012;2012(1):23. 
20. Houk CP, Kunselman AR, Lee PA. The diagnostic value of a brief GnRH analogue 
stimulation test in girls with central precocious puberty: a single 30-minute post-
stimulation LH sample is adequate. J Pediatr Endocrinol Metab 2008;21(12): 
21. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr 
Adolesc Med 1994;148(4):369e76. 
22. Carretto F, Salinas-Vert I, Granada-Yvern ML, et al. The usefulness of the leuprolide 
stimulation test as a diagnostic method of idiopathic central precocious puberty in girls. 
Horm Metab Res 2014;46(13):959e63. 
23. Oerter KE, Uriarte MM, Rose SR, et al. Gonadotropin secretory dynamics during puberty 
in normal girls and boys. J Clin Endocrinol Metab 1990;71(5):1251e8. 
24. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing 
hormone level to diagnose central precocious puberty in girls. Pediatrics 2009;123: 
e1059–63. 
25. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin 
concentrations in the evaluation of precocious puberty. J Pediatr 1995; 127:47–52. 
26. Eksioglu AS, Yilmaz S, Cetinkaya S, Cinar G, Yildiz YT, Aycan Z. Value of pelvic 
sonography in the diagnosis of various forms of precocious puberty in girls. J Clin 
Ultrasound. 2013;41(2):84–93.  
27. de Vries L, Horev G, Schwartz M, Phillip M. Ultrasonographic and clinical parameters 
for early differentiation between precocious puberty and premature thelarche. Eur J 
Endocrinol 2006; 154:891. 
28. Badouraki M, Christoforidis A, Economou I, et al. Evaluation of pelvic ultrasonography 
in the diagnosis and differentiation of various forms of sexual precocity in girls. 
Ultrasound Obstet Gynecol 2008; 32:819. 
29. Pienkowski C, Cartault A, Carfagna L, Ernoult P, Vial J, Lemasson F, et al. Ovarian cysts 
in prepubertal girls. Endocr Dev. 2012; 22:101–11.  
30. DeSanctis V, Corrias A, Rizzo V, Bertelloni S, Urso L, et al. Etiology of central 
precocious puberty in males: the results of the Italian Study Group for Physiopathology 
of Puberty. J Pediatr Endocrinol Metab 2000; 13:687–93. 
31. Atta I, Laghari TM, Khan YN, Lone SW, Ibrahim M, et al. Precocious puberty in 
children. J Coll Physicians Surg Pak 2015; 25:124–8.  
32. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence 
and aetiology. Arch Dis Child 1994; 70:116–8. 
33. Chalumeau M, Chemaitilly W, Trivin C, Adan L, Breart G, et al. Central precocious 
puberty in girls: an evidence-based diagnosis tree to predict central nervous system 
abnormalities. Pediatrics 2002; 109:61–7. 
34. Pedicelli S, Alessio P, Scirè G, Cappa M, Cianfarani S. Routine screening by brain 
magnetic resonance imaging is not indicated in every girl with onset of puberty between 
the ages of 6 and 8 years. J Clin Endocrinol Metab. 2014 Dec;99(12):4455-61.  
35. Cantas-Orsdemir S, Garb JL, Allen HF. Prevalence of cranial MRI findings in girls with 
central precocious puberty: a systematic review and meta-analysis. J Pediatr Endocrinol 
Metab. 2018 Jul 26;31(7):701-710.  
**Meta-analysis of the incidence of intracranial pathology found on MRI in girls with 
CPP 
36. Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after 
long-term treatment with LHRH agonists: the National Institutes of Health experience. J 
Clin Endocrinol Metab 2001;86(10):4711e6. 
37. Watson SE, Greene A, Lewis K, Eugster EA. Bird’s eye view of GnRH analog use in a 
pediatric endocrinology referral center. Endocr Pract. 2015 Jun;21(6):586-9.  
38. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of 
gonadotropin releasing hormone agonist treatment in boys with central precocious 
puberty: final height results. Horm Res. 2002; 58(1):1–7.  
39. Kaplowitz P, Bloch C, Section on Endocrinology, American Academy of Pediatrics. 
Evaluation and Referral of Children with Signs of Early Puberty. Pediatrics 2016; 137. 
40. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in 
young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin 
Endocrinol Metab 1999; 84:415. 
41. Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus 
slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin 
Endocrinol Metab 2001; 86:4127. 
42. Bar A, Linder B, Sobel EH, et al. Bayley-Pinneau method of height prediction in girls 
with central precocious puberty: correlation with adult height. J Pediatr 1995; 126:955.  
43. Nacinovich R, Buzi F, Oggiano S, Rossi S, Apada S, Broggi F, Pilotta A, Neri F, Bomba 
M. Body experiences and psychopathology in idiopathic central precocious and early 
puberty. Minerva Pediatr. 2016; 68:11–18.  
44. Sonis WA, Comite F, Blue J, Pescovitz OH, Rahn CW, Hench KD, Cutler GB, Jr, 
Loriaux DL, Klein RP. Behavior problems and social competence in girls with true 
precocious puberty. J Pediatr. 1985; 106:156–160.  
45. Jackson PL, Ott MJ. Percieved self-esteem among girls diagnosed with precocious 
puberty. J Pediatr Nurs. 1990; 5:190–203.  
46. Blumenthal H, Leen-Feldner EW, Babson KA, Gahr JL, Trainor CD, Frala JL. Elevated 
social anxiety among early maturing girls. Dev Psychol. 2011; 47:1133–1140.  
47. Kaltiala-Heino R, Marttunen M, Rantanen P, et al. Early puberty is associated with 
mental health problems in middle adolescence. Soc Sci Med 2003;57(6):1055e64. 
48. Ehrhardt AA, Meyer-Balhlburg HF, Bell JJ, Cohen SF, Healey JM, Stiel R, Feldman JF, 
Morishima A, New MI. Idiopathic precocious puberty in girls: psychiatric follow-up in 
adolescence. J Am Acad Child Adolesc Psychiatry. 1984; 23:23–33.  
49. Sonis WA, Comite F, Pescovitz OH, Hench K, Rahn CW, Cutler GB, Jr, Loriaux DL, 
Klein RP. Biobehavioral aspects of precocious puberty. J Am Acad Child 
Psychiatry. 1986; 25:674–679.  
50. Comite F, Cassorla F, Barnes KM, Hench KD, Dwyer A, Skerda MC, et al. Luteinizing 
hormone releasing hormone analogue therapy for central precocious puberty. Long-term 
effect on somatic growth, bone maturation, and predicted height. JAMA. 1986 
May;255(19):2613–6. 
51. Carel JC, Blumberg J, Seymour C, et al. Three-month sustained-release triptorelin (11.25 
mg) in the treatment of central precocious puberty. Eur J Endocrinol 
2006;154(1):119e24. 
52. Lee PA, Klein K, Mauras N, et al. Efficacy and safety of leuprolide acetate 3-month 
depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J 
Clin Endocrinol Metab 2012;97(5):1572e80. 
53.  Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses 
in the treatment of central precocious puberty. J Pediatr 2011;159(6).  
54. Duarnd A, Tauber M, Patel B, et al. Meta-analysis of paediatric patients with central 
precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-
release formulation. Horm Res Paediatr 2017;87(4):224e32. 
**Meta-analysis of 3-monthly triptorelin 
55. Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month 
formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab 
2016;29(11):1241e8. 
56. **First report of a 6-monthly depot GnRHa 
57. Lewis KA, Eugster EA. Experience with the once-yearly histrelin (GnRHa) subcutaneous 
implant in the treatment of central precocious puberty. Drug Des Dev Ther 2009; 3:1e5.  
58. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, et al. The histrelin 
implant: a novel treatment for central precocious puberty. Pediatrics. 2005;116(6): e798–
802.  
59. **First report of the use of the histrelin implant to treat CPP 
60. Silverman, LA., Neely, EK., Kletter, GB., Lewis, K., Chitra, S., Terleckyj, O., Eugster, 
EA. J Clin Endocrinol Metab. Long-term continuous suppression with once-yearly 
histrelin subcutaneous implants for the treatment of central precocious puberty: a final 
report of a phase 3 multicenter trial. Epub 2015 Mar 24 
61. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. Efficacy and 
safety of histrelin subdermal implant in children with central precocious puberty: a 
multicenter trial. J Clin Endocrinol Metab. 2007; 92(5):1697–704.  
62. Lewis KA, Goldyn AK, West KW, Eugster EA. A single histrelin implant is effective for 
2 years for treatment of central precocious puberty. J Pediatr. 2013; 163(4):1214–6.  
63. Lewis KA, Eugster EA. Random luteinizing hormone often remains pubertal in children 
treated with the histrelin implant for central precocious puberty. J Pediatr. 2013 
Mar;162(3):562-5.  
64. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term 
observation of 87 girls with idiopathic central precocious puberty treated with 
gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone 
mineral content, and reproductive function. J Clin Endocrinol Metab. 2008; 93(1):190–5.  
65. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Le-vidou G, Vakaki M, et al. 
The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood 
and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 
2010; 95(1): 109–17.  
66. Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and 
time of menarche of girls with id-iopathic central precocious puberty after gonadotropin-
releasing hormone analogue treatment. Gynecol Endocrinol. 2011; 27(8):524–8.  
67. Lazar L, Meyerovitch J, de Vries L, Phillip M, Lebenthal Y. Treated and untreated 
women with idiopathic precocious puberty: long-term follow-up and reproductive 
outcome between the third and fifth decades. Clin Endocrinol (Oxf). 2014 
Apr;80(4):5706.  
**Long-term follow up of reproductive function in women treated with a GnRHa for 
CPP 
